Growth Hormone and Disease Severity in Early Stage of Multiple Sclerosis

Abstract

Evidence suggests that neurohormones such as GH and IGF-I are involved in the neuroreparative processes in multiple sclerosis (MS). GH and IGF-I blood levels in naïve MS patients with different disease courses were investigated in this study. Serum GH and IGF-I in untreated MS patients (n=64), healthy controls (HC, n=62), and patients affected by other neurological diseases (OND, n=46) were evaluated with a solid-phase-enzyme-labeled-chemiluminescent-immunometric assay. No differences were detected in GH across MS, OND, and HC (MS=0.87±1.32 ng/mL; OND=1.66±3.7; and HC=1.69±3.35; P=0.858) when considering gender, disease duration, and disease course. However, GH was lower (P=0.007) in patients with more severe disease (expanded disability scale score, EDSS≥4.0) compared with milder forms (EDSS<4). IGF-I l did not differ across the 3 groups (P=0.160), as far as concern disease course, disability, and gender were. Lower IGF-I levels were detected in subjects older than 50 years compared to younger ones for all 3 groups. Lower GH was detected in patients with more severe MS, and age was confirmed as the main factor driving IGF-I levels in all subjects. These findings, relying on the natural course of the disease, could help in shedding lights on the mechanisms involved in autoreparative failure associated with poorer prognosis in MS.